Biomerica Inc. reported a net sales figure of approximately $5.31 million for the fiscal year ending May 31, 2025, reflecting a decrease of 2% from the $5.42 million recorded in the previous fiscal year. The decline in revenue was primarily attributed to reduced retail market activity and lower international over-the-counter sales, which were impacted by potential tariff issues and fluctuations in clinical laboratory demand. However, this decrease was partially offset by a 44% increase in contract manufacturing revenues, which rose to $1.07 million, and growing demand for the inFoods® IBS product.
The company's operating expenses also saw a significant reduction, with selling, general, and administrative expenses decreasing by 16% to approximately $4.61 million, down from $5.49 million in the prior year. This reduction was largely due to a workforce reduction of about 15% and decreased stock compensation and marketing expenses. Research and development expenses also fell by 31% to approximately $1.02 million, reflecting a shift from intensive product development to commercialization efforts for inFoods® IBS and hp+detect™.
Biomerica's operational metrics indicate a customer base of approximately 76, with a notable concentration of sales through key distributors. As of May 31, 2025, four distributors accounted for about 69% of gross accounts receivable, highlighting the company's reliance on a limited number of partners for revenue generation. The company has also reported a backlog of unshipped orders amounting to approximately $1.32 million, with a significant portion intended for shipment to Asia.
Strategically, Biomerica has focused on expanding its product offerings and market presence. The company received FDA clearance for its hp+detect™ test in December 2023, which is designed to detect Helicobacter pylori infections, a significant health concern affecting a large portion of the population. Additionally, Biomerica is actively pursuing reimbursement opportunities for its inFoods® IBS product through Medicare and private insurance, which could enhance its revenue potential.
Looking ahead, Biomerica acknowledges the challenges posed by evolving global economic conditions, including uncertainties related to international trade policies and supply chain dynamics. The company is implementing contingency plans to mitigate potential impacts on its operations and is exploring strategic opportunities to enhance shareholder value. However, the company has expressed substantial doubt about its ability to continue as a going concern without securing additional financing and achieving profitable operations in the near future.
About BIOMERICA INC
Biomerica, Inc. is a global biomedical technology company specializing in the development, manufacturing, and marketing of advanced diagnostic and therapeutic products. Its core offerings include rapid diagnostic test kits for detecting diseases, food intolerances, and medical conditions using blood, urine, nasal, or fecal samples. Serving clinical laboratories and point-of-care markets worldwide, Biomerica leverages patented technologies like inFoods® to provide accurate, easy-to-use tests that support early diagnosis and personalized treatment, enhancing patient care and reducing healthcare costs.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.